Clinical Trials Browser

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT02689427 2024-09-19

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase 3 Suspended

201 enrolled 19 charts

Breast

Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

782 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Phase 2 Completed

127 enrolled 12 charts

Breast

Breast Neoplasms

NCT05205200 2024-02-08

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Phase 2 Recruiting

338 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2 Terminated

15 enrolled 9 charts

Breast

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

98 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01106898 2023-09-28

Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery

Phase 2 Completed

112 enrolled 8 charts

Breast

Breast Neoplasms

NCT00934895 2023-09-18

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Phase 1/2 Terminated

27 enrolled 12 charts

Breast

Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Phase 1 Completed

9 enrolled 17 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00499291 2023-05-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Phase NA Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Teratoma, Testicular, Teratoma, Ovarian, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Teratoma, Testicular Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2 Completed

47 enrolled 13 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Phase 2 Active not recruiting

62 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02474173 2022-11-04

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1 Terminated

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00785291 2022-10-10

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Phase 3 Completed

799 enrolled 18 charts

Breast

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Phase 2 Unknown

319 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05251766 2022-02-23

Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

Phase 1 Unknown

30 enrolled

Breast

Breast Neoplasms

NCT00629499 2021-11-24

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Phase 2 Completed

63 enrolled 7 charts

Breast

Breast Neoplasms

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Phase 4 Terminated

4 enrolled 9 charts

Breast

Breast Neoplasms

NCT00723125 2021-04-29

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Phase 2 Completed

60 enrolled 7 charts

Breast

Breast Neoplasms

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2/3 Withdrawn

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00470301 2021-02-16

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Completed

60 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01697293 2020-09-24

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Phase 1/2 Terminated

34 enrolled

Breast

Breast Neoplasms

NCT00005970 2020-08-14

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3 Completed

3,436 enrolled

Breast

Breast Neoplasms

NCT00331630 2020-03-06

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase EARLY_PHASE1 Completed

30 enrolled 13 charts

Breast

Breast Neoplasms

NCT03505528 2019-11-13

Epi-PRIMED

Phase 1 Completed

8 enrolled

Breast

Breast Neoplasms

NCT02640053 2019-09-30

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome

Phase NA Completed

46 enrolled 13 charts

Breast

Breast Neoplasms

Clinical Trials

Study of DF1001 in Patients With Advanced Solid Tumors

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

9-ING-41 in Patients with Advanced Cancers

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

SMMART Adaptive Clinical Treatment (ACT) Trial

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

SPARK

Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

MULAN

Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Epi-PRIMED

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome